Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.11.2023 | Clinical study

BP elevation does not increase risk of MACE during VEGF TKI therapy

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Early hypertension does not appear to increase the risk of major adverse cardiovascular events (MACE) during vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) therapy in patients with advanced renal cell carcinoma (RCC) or thyroid cancer, according to findings of a US study published in the Journal of the National Comprehensive Cancer Network (JNCCN) . …
Literatur
Zurück zum Zitat Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs Journal of the National Comprehensive Cancer Network 21: No. 10, 21 Oct 2023. Available from: URL: https://doi.org/10.6004/jnccn.2023.7047 Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs Journal of the National Comprehensive Cancer Network 21: No. 10, 21 Oct 2023. Available from: URL: https://​doi.​org/​10.​6004/​jnccn.​2023.​7047
Metadaten
Titel
BP elevation does not increase risk of MACE during VEGF TKI therapy
Publikationsdatum
01.11.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-48586-6

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Temozolomide

Case report

Multiple drugs

Case report

Multiple drugs